Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...

Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...

United Airlines says its third-quarter profit fell 15% from a year ago. But its revenue trends improved thanks to low-fare ...

According to Cox Automotive’s latest data, the Honda Prologue was the 5th best-selling EV in the third quarter. Honda sold 12,644 Prologue’s in Q3, topping Hyundai’s IONIQ 5 (11,590) and the Rivian ...

Wall Street stocks were in the red at the close of trading on Tuesday as Q3 earnings season kicked up a gear. At the close, ...

Johnson & Johnson reported better-than-expected third-quarter sales and raised its full-year revenue guidance.

Operator Good morning and welcome to Johnson & Johnson's third quarter 2024 earnings conference call. All participants will ...

Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which ...

Despite the topline growth, J&J’s net earnings fell 37.5% to $2.6 billion, down from $4.3 billion in Q3 2023. Johnson & ...

In Q3 2024, Johnson & Johnson's innovative medicine segment reported a 6.3% operational sales growth, with oncology and immunology products leading the way. Substantial demand for Darzalex and other ...